| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 44.9 | 89.6 | 43.1 |
| Other income | 2.9 | 0.5 | 2.6 |
| Total income | 47.8 | 90.1 | 45.7 |
| Profit before exceptional items & tax | 3.9 | 20.2 | 3.4 |
| Profit before tax | 3.9 | 20.2 | 3.4 |
| Net profit | 2.0 | 14.9 | 2.3 |
| Operating margin | 8.2% | 22.4% | 7.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -13.00% |
|---|---|
| Net profit, quarter on quarter | -86.60% |
| Revenue, year on year | +4.20% |
| Operating profit, year on year | +25.00% |
| Operating profit, quarter on quarter | -94.90% |
BSE results filing, NSE: KILITCH. Figures extracted from the filing.
Kilitch Drugs(I) Ltd: key numbers
- Share price
- ₹255.60
- Market cap
- ₹893.6 Cr
- Revenue (annual)
- ₹235.5 Cr
- Net profit (annual)
- ₹30.17 Cr
- P/E (TTM)
- 29.7×Sector 47.4×
- Promoter holding
- 63.77%+0.00% QoQ
- FII holding
- 0.12%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kilitch Drugs(I) Ltd
All →Kilitch Drugs(I) Annual General Meeting
Kilitch Drugs (India) held its 34th Annual General Meeting on August 27, 2026, transacting four business resolutions including financial statement approval and director re-appointment.
Kilitch Drugs(I) Other Announcement
Kilitch Drugs filed its Monitoring Agency Report for the quarter ended June 30, 2026, concerning its Rights Issue proceeds of Rs. 49.92 Crore.
- Value
- ₹49.92 Cr
Kilitch Drugs(I) Board Meeting Date
Kilitch Drugs (India) Ltd has scheduled a board meeting for August 13, 2026. The board will consider and approve unaudited financial results for the June quarter.
Kilitch Drugs(I) Annual Report
Kilitch Drugs submitted its Annual Report for FY 2025-26 and the notice for the 34th Annual General Meeting to the stock exchanges.
Kilitch Drugs(I) Management Change
Kilitch Drugs (India) Limited has re-appointed Arivind Kumar & Co. as its Cost Auditor for a 12-month term.
Kilitch Drugs(I) Annual General Meeting
Kilitch Drugs (India) Ltd announced its 34th Annual General Meeting scheduled for August 27, 2026, along with relevant book closure dates. The board also re-appointed cost auditors.